Elevance Health Inc.

Fundamentals6.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Solid annual earnings
  • Quarterly FCF pressure
  • Large intangibles

AI
AI Summary

6.0

ELV's investment thesis has shifted from membership-led growth to an execution-driven capital-allocation story where near‑term EPS re‑rating hinges on restoring consistent quarterly free cash flow and proving Carelon/digital cost savings can offset steep Medicaid-related margin headwinds; monitor sequential quarterly FCF, Medicaid membership/margin trends, and timely MA/Star improvements as make‑or‑break catalysts. If FCF and margin recovery materialize alongside clear Carelon operational leverage, upside is credible; failure to deliver would likely force multiple compression and potential impairments.

Carelon
Medicaid
Execution‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Solid annual earnings
  • Quarterly FCF pressure
  • Large intangibles

Elanco is a reasonably valued, dividend‑paying animal-health company with solid annual earnings, ample cash and manageable leverage but notable near-term risk from deteriorating quarterly margins, negative quarterly FCF and a large intangible asset base.

stable
volatile

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below last-month SMA
  • Support near $279
  • Resistance $320–$375

ELV is trading below its last-month SMA (~$300), indicating a short-term downtrend with nearby support at $279.02 and stronger resistance in the $320–$375 band after a ~14% drop from late February.

Risk
Watch
Support Level: $279.02
Resistance Level: $300; $320–$375

~14% decline from ~2026-02-20 to 2026-03-20 indicating short-term distribution

Sentiment & News

6.0

Key News Insights:

  • Mixed institutional activity
  • Rising short interest
  • Legal/investor alerts

Institutional flows into Elevance Health surged in late Feb–mid Mar 2026 with several new and increased stakes offset by large manager trims, a sharp 29.3% rise in short interest, ongoing legal/investor alerts, and an overall “Moderate Buy” analyst consensus.

ShortInterest

Elevated trading activity and increased shorting heighten near-term volatility risk despite modest analyst optimism